Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy of bulevirtide combination with pegylated interferon in participants with chronic hepatitis delta (CHD).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03852433
Study type Interventional
Source Gilead Sciences
Contact
Status Completed
Phase Phase 2
Start date May 31, 2019
Completion date September 23, 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04170452 - Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta
Withdrawn NCT05953545 - Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis Phase 2
Active, not recruiting NCT03852719 - Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) Phase 3